To describe two patients with Behçet’s disease who underwent cataract surgery one week after infliximab administration. Methods:
Patients received preoperative antibiotic therapy with 0.5% levofloxacin eye drops and 500 mg levofloxacin oral tablets, followed by cataract surgery one week after infliximab administration. We observed ocular findings following cataract surgery, phacoemulsification-aspiration, and posterior chamber intraocular lens implantation. Results:
There were no intraoperative complications. Neither ocular inflammatory attacks nor infectious complications were found in the operated eyes of both patients during follow-up. Conclusion:
Administration of infliximab one week before cataract surgery is safe and effective for patients with Behçet’s disease.
Masahiro Zako, MD
Department of Ophthalmology, Aichi Medical University
Nagakute, Aichi 480-1195 (Japan)
Tel. +81 52264 4811, E-Mail firstname.lastname@example.org
Published online: May 24, 2011
Number of Print Pages : 3
Case Reports in Ophthalmology
Vol. 2, No. 2, Year 2011 (Cover Date: May - August)
Journal Editor: Loewenstein A. (Tel Aviv)
ISSN: NIL (Print), eISSN: 1663-2699 (Online)
For additional information: http://www.karger.com/COP
Open Access License / Drug Dosage
Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license
), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.